Scientists at City of Hope have uncovered new molecular targets on a cell receptor that plays a major role in cardiovascular regulation. The findings could lead to improved drugs for heart disease.
The study, published in Science Signaling, specifically revealed mechanisms on Angiotensin II type 1, or AT1R, which allow hormones and drugs to transfer information on the cell surface. The team used a combination of computational methods and experiments to identify newer drug binding sites in the receptor AT1R that significantly expands the scope of potential targets for drug development, particularly new therapeutics that influence the activity of the receptor in heart disease.
“We identified previously unknown domains and mechanisms within AT1R that enable the receptor to bind with molecules and transmit specific signals. Our work strongly suggests these regions offer promising targets for new treatments for cardiovascular diseases,” co-author Nagarajan Vaidehi said. “Equally exciting, is the finding that multiple drug binding sites exist on these proteins that bind to AT1R, paving the way for us to develop a new class of medicines with less side effects for patients.”
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Current medicines act on the AT1R receptor to elicit specific cellular responses, but, until now, scientists have not decoded the mechanisms behind them. In this study, the team blended computational modeling with leading-edge approaches in structural biology and pharmacology to detect signaling within AT1R that dictates the receptor’s responses to key intracellular pathways.